{"database": "lobbying", "table": "lobbying_activities", "rows": [[3010669, "38721f94-9c39-4b68-a6a1-17ed4dff9038", "Q2", "MEHLMAN CONSULTING, INC.", 284950, "THE CAMPAIGN FOR SUSTAINABLE RX PRICING", 2023, "second_quarter", "CPT", "Patent abuse issues. S. 150 - Affordable Prescriptions for Patients Act of 2023. S. 79 - Interagency Patent Coordination Act. Initiatives To Ensure the Robustness and Reliability of Patents Rights (PTO-P-2022-0025). Joint USPTO-FDA Collaboration Initiatives. Notice of Public Listening Session and Request for Comment (PTO-P-2022-0037).", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE", 50000, null, 0, 0, "2023-07-18T14:24:02-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3010669"], "units": {}, "query_ms": 14.366830000653863, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}